A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and 18F-PSMA-PET/CT

In a comparison study of the use of prostate-specific membrane antigen (PSMA) PET/CT vs. bone scintigraphy to detect bone lesion in patients with high-risk prostate cancer, researchers found that ¹⁸F-PSMA-PET/CT imaging findings resulted in treatment changes, due to up- or downstaging of disease, for almost 20% of patients in the trial.